Study targets EGFR and FGFR cellular pathways to treat rare diseaseContinue reading
Author Archives: D3Bio
HTG Molecular Diagnostics Completes Initial Series E Preferred Stock Offering
TUCSON, AZ, Feb 11, 2014 (Media Release) — HTG Molecular Diagnostics (“HTG”) today announced the initial closing of its Series E offering with existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght. Proceeds will support commercial and product development initiatives.Continue reading
TGen study uncovers possible genetic markers in breast cancer that spreads to the brain
New treatments might be possible for patients who now have little hopeContinue reading
Mathematical Model Developed by UA Physicists Could Help Treat Lyme Disease
A computer simulation of Lyme disease rash might help doctors better predict the spread of the bacteria in the early stages when antibiotics are most effective.
By University Communications, February 6, 2014Continue reading
NuvOx Makes the Transition from the Laboratory to the Clinic and is Pounding the Pavement to Raise $15MM.
NuvOx Pharma, a Tucson-based biotech startup, founded in 2008 is metamorphosing from an R&D startup to one that is testing the Company’s nanotechnology therapeutic platform in the clinic.Continue reading
Study Looks at Cancer-Preventive Effects of Anti-Diabetes Drug
Chow’s study will focus on overweight premenopausal women with metabolic syndrome.Continue reading
NuvOx plans USD 15m Series A this year for glioblastoma
NuvOx Pharma will target a USD 15m Series A raise in 2014 for its glioblastoma multiforme (GBM) candidate, NVX108,
according to Chief Business Officer David Wilson. (Source: BioPharm Insight) Continue reading
Ulthera® System Receives Third FDA Clearance
Non-Invasive Ultherapy® Ultrasound Procedure Recognized for Imaging Capabilities